Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525752 | 0.84 | CA1 (0.40) | CYP11B1GSK3AGSK3B | |
| SCHEMBL5688427 | 0.77 | LIPE (0.41) | HTR1ADRD2HTR2CHTR7HRH1 | |
| SCHEMBL5648177 | 0.73 | POLB (0.48) | — | |
| SCHEMBL5715251 | 0.73 | MAPT (0.46) | HTR1ADRD2HTR2CHTR7HRH1 | |
| SCHEMBL5690370 | 0.71 | GSK3A (0.43) | HTR1ADRD2HTR2CHTR7HRH1 | |
| SCHEMBL21591529 | 0.68 | TDP1 (0.50) | — | |
| SCHEMBL12649387 | 0.68 | CASP3 (0.44) | CYP11B1 | |
| SCHEMBL17828181 | 0.68 | HRH3 (0.57) | — | |
| SCHEMBL31667550 | 0.68 | KDM4E (0.46) | HTR1ADRD2HTR7 | |
| SCHEMBL16797049 | 0.67 | MEN1 (0.45) | CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160865-A1 | Pyridinyl carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636205-A1 | PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111031-A1 | PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160865-A1 | Pyridinyl carbamates | LIPE, PNLIP, LPL | HTR1A 1869/4885DRD2 4381/4885HTR2C 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.